Optic Neuropathy - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Optic Neuropathy - Pipeline Review, H1 2019’, provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy

- The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects

- The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Optic Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Antoxis Ltd

Quark Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Regenera Pharma Ltd

Regeneron Pharmaceuticals Inc

Allergan Plc

Antoxis Ltd

Quark Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Regenera Pharma Ltd

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuropathy – Overview

Optic Neuropathy – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuropathy – Overview

Optic Neuropathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuropathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuropathy – Companies Involved in Therapeutics Development

Allergan Plc

Antoxis Ltd

Quark Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Regenera Pharma Ltd

Regeneron Pharmaceuticals Inc

Optic Neuropathy – Drug Profiles

aflibercept – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimonidine tartrate implant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSIC-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELN-41 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fab-3H4 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22A4 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1007 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPh-201 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dominant Optic Atrophy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurological and Ophthalmological Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Optic Neuropathy – Dormant Projects

Optic Neuropathy – Discontinued Products

Optic Neuropathy – Product Development Milestones

Featured News & Press Releases

Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting

Aug 06, 2018: Regenera Pharma enrols first patient in Phase lll trial of RPh201

Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007

Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’

Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007

Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant

Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications

Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION

Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy

Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies

Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Optic Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Optic Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Optic Neuropathy – Pipeline by Allergan Plc, H1 2019

Optic Neuropathy – Pipeline by Antoxis Ltd, H1 2019

Optic Neuropathy – Pipeline by Quark Pharmaceuticals Inc, H1 2019

Optic Neuropathy – Pipeline by Recursion Pharmaceuticals Inc, H1 2019

Optic Neuropathy – Pipeline by Regenera Pharma Ltd, H1 2019

Optic Neuropathy – Pipeline by Regeneron Pharmaceuticals Inc, H1 2019

Optic Neuropathy – Dormant Projects, H1 2019

Optic Neuropathy – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Optic Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Optic Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports